Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
Peters G, Cheng W, Boateng K, Knowlton C, Campbell A, Hayman T, Park H. Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e46-e47. DOI: 10.1016/j.ijrobp.2023.06.750.Peer-Reviewed Original ResearchStereotactic body radiation therapyPhase Ib/II trialCentral lung tumorsCancer-specific survivalProgression-free survivalLocal recurrenceLung tumorsInterim analysisII trialAdverse eventsOverall survivalDistant controlLocal controlGrade 2 adverse eventsUltra-central lung tumorsRisk dose constraintsRate of gradeSecondary lung tumorsCo-primary endpointsHigh toxicity ratesBiologically equivalent doseBody radiation therapyMATERIAL/METHODSRTOG 0236RTOG 0813